Form 4: ZyVersa Therapeutics Director Acquires Stock Options After Reverse Stock Splits
SEC Form 4
Robert G. Finizio, a director of ZyVersa Therapeutics, reports the acquisition of stock options after accounting for two reverse stock splits.
Summary
- Robert G. Finizio, a director at ZyVersa Therapeutics, filed a Form 4 disclosing changes in beneficial ownership.
- The report details the acquisition of 132 stock options on May 24, 2023, at an exercise price of $152.46.
- These options vest annually in three equal installments starting May 24, 2024.
- The reported share and dollar amounts reflect a 1-for-35 reverse stock split on December 4, 2023, and a 1-for-10 reverse stock split on April 25, 2024.
- A Power of Attorney was executed on December 13, 2022, granting Stephen C. Glover, Peter Wolfe, and Karen A. Cashmere the authority to act on Finizio's behalf regarding SEC filings.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock option acquisition by a director, with a neutral sentiment.
Industry Context
Form 4 filings are standard practice for company insiders (directors, officers, and principal stockholders) to report transactions in their company's stock, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| December 13, 2022 | Date of execution of Power of Attorney. |
| May 24, 2023 | Date of the earliest transaction (acquisition of stock options). |
| December 4, 2023 | Date of 1-for-35 reverse stock split. |
| April 25, 2024 | Date of 1-for-10 reverse stock split. |
| May 24, 2024 | Commencement date for annual vesting of stock options. |
| May 24, 2033 | Expiration date of the stock options. |
| July 18, 2024 | Date of Form 4 filing. |
Keywords
Form 4, ZyVersa Therapeutics, Stock Options, Beneficial Ownership, Reverse Stock Split, Director, Finizio, ZVSA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.